12952110

Source:http://linkedlifedata.com/resource/pubmed/id/12952110

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001675, umls-concept:C0035457, umls-concept:C0087111, umls-concept:C0205653, umls-concept:C0966225, umls-concept:C2825096
pubmed:issue	2
pubmed:dateCreated	2003-9-3
pubmed:abstractText	Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9503580
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Terfenadine, http://linkedlifedata.com/resource/pubmed/chemical/anti-IgE, http://linkedlifedata.com/resource/pubmed/chemical/fexofenadine, http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1081-1206
pubmed:author	pubmed-author:CasaleThomasT, pubmed-author:ChervinskyPaulP, pubmed-author:Fowler-TaylorAngelA, pubmed-author:FoxHowardH, pubmed-author:HedgecockSimonS, pubmed-author:ShenHenryH, pubmed-author:TownleyRobertR, pubmed-author:TripathyItaI
pubmed:issnType	Print
pubmed:volume	91
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	160-7
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:12952110-Adolescent, pubmed-meshheading:12952110-Adult, pubmed-meshheading:12952110-Aged, pubmed-meshheading:12952110-Anti-Asthmatic Agents, pubmed-meshheading:12952110-Antibodies, Anti-Idiotypic, pubmed-meshheading:12952110-Antibodies, Monoclonal, pubmed-meshheading:12952110-Antibodies, Monoclonal, Humanized, pubmed-meshheading:12952110-Child, pubmed-meshheading:12952110-Double-Blind Method, pubmed-meshheading:12952110-Female, pubmed-meshheading:12952110-Humans, pubmed-meshheading:12952110-Injections, Subcutaneous, pubmed-meshheading:12952110-Male, pubmed-meshheading:12952110-Middle Aged, pubmed-meshheading:12952110-Nasal Mucosa, pubmed-meshheading:12952110-Patient Satisfaction, pubmed-meshheading:12952110-Quality of Life, pubmed-meshheading:12952110-Rhinitis, Allergic, Perennial, pubmed-meshheading:12952110-Terfenadine, pubmed-meshheading:12952110-Treatment Outcome
pubmed:year	2003
pubmed:articleTitle	Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
pubmed:affiliation	Northeast Medical Research Associates, Dartmouth, Massachusetts 02747, USA. cchervinsky@pol.net
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III